Drug Details

General Information of the Drug (ID: DR3007)
Name
Dapsone
Synonyms
dapsone; 80-08-0; 4,4'-Sulfonyldianiline; Diaphenylsulfone; Dapson; 4,4'-Diaminodiphenyl sulfone; 4-Aminophenyl sulfone; 4,4'-Diaminodiphenylsulfone; Diaphenylsulfon; Sulfona; DADPS; Avlosulfone; Diphenasone; Sulfadione; Sulphadione; Disulone; Udolac; p-Aminophenyl sulfone; Bis(4-aminophenyl) sulfone; Avlosulfon; Croysulfone; Dapsonum; Dumitone; Novophone; Aczone; Diphone; Eporal; Diaphenylsulphon; Diaphenylsulphone; Metabolite C; Sulfonyldianiline; Sumicure S; Bis(p-aminophenyl) sulfone; Sulphonyldianiline; p,p-Sulphonylbisbenzamine; Sulfona-MAE; Avlosulphone; Croysulphone; Dubronax; 4,4'-Dapsone; Diaminodiphenyl sulfone; Tarimyl; p,p-Sulphonylbisbenzenamine; Sulfone ucb; 4,4'-Sulfonylbisaniline; p,p'-Diaminodiphenyl sulfone; 4-(4-aminophenyl)sulfonylaniline; Dapsona; Benzenamine, 4,4'-sulfonylbis-; Diaminodiphenylsulfone; Di(p-aminophenyl)sulphone; Bis(4-aminophenyl)sulfone; Di(p-aminophenyl) sulfone; p,p-Sulphonyldianiline; 4,4'-Sulfonylbisbenzamine; Di(4-aminophenyl) sulfone; p,p'-sulfonyldianiline; NSC-6091; 4,4'-Sulfonylbisbenzenamine; p,p-Sulfonylbisbenzamine; Diaminodifenilsulfona; DDS, pharmaceutical; p,p-Sulfonylbisbenzenamine; Araldite HT 976; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl)sulphone; Bis(4-aminophenyl)sulphone; p,p-Diaminodiphenyl sulphone; N,N'-Diphenyl sulfondiamide; 1,1'-Sulfonylbis(4-aminobenzene); 4,4'-Sulphonyldianiline; 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; DDS; 4,4'-Diaminodiphenyl sulphone; WR 448; 4,4-Diaminodifenylsulfon; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; NSC 6091D; NCI-C01718; 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); Aniline, 4,4'-sulfonyldi-; HT 976; 4,4'-diamino diphenyl sulphone; F 1358; 4,4'-Sulfonyldianiline (Dapsone); 1358F; 4-[(4-aminobenzene)sulfonyl]aniline; MFCD00007887; 4,4'-Sulfonylbisbenzeneamine; 4,4'-Sulfonyldianilin; UNII-8W5C518302; 4-[(4-aminophenyl)sulfonyl]aniline; CHEMBL1043; 4-Aminophenyl sulfone, 97%; MLS000069409; CHEBI:4325; DTXSID4020371; Sulfanona-mae; NSC6091; Sulfon-mere; 4,4'-DDS; Di(4-aminophenyl)sulfone; 4-[(4-Aminophenyl)sulfonyl]phenylamine; 4-(4-amino-benzenesulfonyl)-phenylamine; NCGC00016322-08; SMR000059064; Hardener HT 976; DDS (pharmaceutical); Sulphon-mere; DSSTox_CID_371; 8W5C518302; Dapsonum [INN-Latin]; Dapsona [INN-Spanish]; DSSTox_RID_75547; DSSTox_GSID_20371; DSS (VAN); 4-Aminophenylsulfone; DDS, diaphenylsulfone; 4,4'-Diaminodiphenyl suphone; Atrisone; Diaminodifenilsulfona [Spanish]; 4,4-Diaminodifenylsulfon [Czech]; CAS-80-08-0; HY 976; CCRIS 192; Dapsone (USP); Aczone (TN); HSDB 5073; Diaphenylsulfone (JAN); SR-01000002976; NSC 6091; Sulfone, diphenyl, 4,4'-diamino-; EINECS 201-248-4; (4-sulfanilylphenyl)amine; AZT + Dapsone cominbation; BRN 0788055; Servidapson; AI3-08087; diaphenylsulfone;; Diaphenyl sulfone; Dapsone [USAN:USP:INN:BAN]; Dapsone-d8; Dapsone,(S); Prestwick_152; ALBB-005917; Dapsone-[d4]; IN-201; 1632119-29-9; Dapsone-13C12; BIS SULFONE; 4,4''-dapsone; Dapsone-[15N2]; Spectrum_000888; ACMC-209piw; Aniline,4'-sulfonyldi-; Opera_ID_1950; Prestwick0_000035; Prestwick1_000035; Prestwick2_000035; Prestwick3_000035; Spectrum2_001133; Spectrum3_000375; Spectrum4_000310; Spectrum5_000825; WLN: ZR DSWR DZ; 4,4''-sulfonyldianiline; 4,4''-sulfonylbisaniline; 4'-Diaminodiphenyl sulfone; EC 201-248-4; 4,4'-Sulfonyldiphenylamine; Benzenamine,4'-sulfonylbis-; Oprea1_143052; SCHEMBL21428; BSPBio_000129; BSPBio_002129; CBDivE_013582; Dianiline, 4,4'-sulfonyl-; KBioGR_000900; KBioSS_001368; MLS001055349; MLS001076146; 4,4''-Sulfonylbisbenzenamine; 4,4'-Sulfonylbis-benzenamine; 4,4'-Sulfonylbis[benzamine]; BIDD:GT0770; DivK1c_000573; p,p''-diaminodiphenyl sulfone; SPECTRUM1500222; SPBio_001025; SPBio_002050; 4,4''-diaminodiphenyl sulfone; 4,4'-diamino diphenyl sulfone; BPBio1_000143; ZINC6310; GTPL10934; HMS501M15; KBio1_000573; KBio2_001368; KBio2_003936; KBio2_006504; KBio3_001349; NSC-6091D; 4-(4-aminophenylsulfonyl)aniline; J04BA02; NINDS_000573; HMS1568G11; HMS1920C14; HMS2091K04; HMS2095G11; HMS2231G09; HMS3259C13; HMS3369B11; HMS3712G11; Pharmakon1600-01500222; ACT07431; AMY40781; EBD28910; HY-B0688; 1,1''-sulfonylbis(4-aminobenzene); Tox21_110371; Tox21_201347; Tox21_300558; 4-(4-aminophenylsulfonyl)benzenamine; ANW-37350; BBL002412; BDBM50029764; CCG-40260; CD0112; NSC756716; s4612; SBB003168; STK387118; AKOS000119322; Tox21_110371_1; DB00250; HT 9664; KS-1450; LS10738; MCULE-7294380437; NC00488; NSC-756716; IDI1_000573; NCGC00016322-01; NCGC00016322-02; NCGC00016322-03; NCGC00016322-04; NCGC00016322-05; NCGC00016322-06; NCGC00016322-07; NCGC00016322-09; NCGC00016322-10; NCGC00016322-13; NCGC00023946-03; NCGC00023946-04; NCGC00023946-05; NCGC00023946-06; NCGC00254533-01; NCGC00258899-01; AC-10922; AK175100; 4-[(4-Aminophenyl)sulfonyl]phenylamine #; SBI-0051331.P003; DB-056406; AB00051962; D0089; Dapsone, VETRANAL(TM), analytical standard; FT-0624447; FT-0665473; R1186; ST50308134; 4 inverted exclamation marka-Sulfonyldianiline; C07666; D00592; AB00051962_19; A839828; Q422226; 4 inverted exclamation marka-Diaminodiphenyl sulfone; Q-200435; SR-01000002976-2; SR-01000002976-4; BRD-K62363391-001-05-8; BRD-K62363391-001-15-7; 4 4-Diamino Diphenyl Sulfone 99.5%min Cas:80-08-8; Dapsone, British Pharmacopoeia (BP) Reference Standard; Dapsone, European Pharmacopoeia (EP) Reference Standard; F0266-3067; 2-(PIPERAZIN-1-YL)-ACETICACIDN-(2-PHENYLETHYL)-AMIDE; Dapsone, United States Pharmacopeia (USP) Reference Standard; Dapsone, Pharmaceutical Secondary Standard; Certified Reference Material
    Click to Show/Hide
Molecular Type
Small molecule
Disease Pneumonia [ICD-11: CA40] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability
Bioavailability
The bioavailability of drug is 70-80%
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.48 mL/min/kg
Elimination
The drug is excreted via renal
Half-life
The concentration or amount of drug in body reduced by one-half in 28 (range 10 - 50) hours
Metabolism
The drug is metabolized via the hepatic
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.13647 micromolar/kg/day
Unbound Fraction
The unbound fraction of drug in plasma is 0.25%
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.83 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 0.2 mg/mL
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C12H12N2O2S
PubChem CID
2955
Canonical SMILES
C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
InChI
1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
InChIKey
MQJKPEGWNLWLTK-UHFFFAOYSA-N
CAS Number
CAS 80-08-0
ChEBI ID
CHEBI:4325
TTD Drug ID
D0MA9N
DrugBank ID
DB00250
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Colchicine      Colchicum autumnale     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Male Sprague-Dawley (SD) rats weighing 200-220 g were used in this study.
                    Experimental
                    Result(s)		 Colchicine combined with atorvastatin may have stronger protective effects on improving endothelial function and ameliorating inflammation in rats with hyperlipidemia.
Target and Pathway
Target(s) Pneumocystis carinii Dihydropteroate synthase (PC DHPS)  Molecule Info  [3]
References
Reference 1 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
Reference 2 Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia. Lipids Health Dis. 2014 Apr 17;13:67.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link